266 related articles for article (PubMed ID: 30718758)
1. Metformin enhances the radiosensitizing effect of cisplatin in non-small cell lung cancer cell lines with different cisplatin sensitivities.
Riaz MA; Sak A; Erol YB; Groneberg M; Thomale J; Stuschke M
Sci Rep; 2019 Feb; 9(1):1282. PubMed ID: 30718758
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin-mediated radiosensitization of non-small cell lung cancer cells is stimulated by ATM inhibition.
Toulany M; Mihatsch J; Holler M; Chaachouay H; Rodemann HP
Radiother Oncol; 2014 May; 111(2):228-36. PubMed ID: 24857596
[TBL] [Abstract][Full Text] [Related]
3. Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK.
Storozhuk Y; Hopmans SN; Sanli T; Barron C; Tsiani E; Cutz JC; Pond G; Wright J; Singh G; Tsakiridis T
Br J Cancer; 2013 May; 108(10):2021-32. PubMed ID: 23632475
[TBL] [Abstract][Full Text] [Related]
4. Combined Effects of Suberoylanilide Hydroxamic Acid and Cisplatin on Radiation Sensitivity and Cancer Cell Invasion in Non-Small Cell Lung Cancer.
Feng J; Zhang S; Wu K; Wang B; Wong JY; Jiang H; Xu R; Ying L; Huang H; Zheng X; Chen X; Ma S
Mol Cancer Ther; 2016 May; 15(5):842-53. PubMed ID: 26839308
[TBL] [Abstract][Full Text] [Related]
5. Nootkatone, an AMPK activator derived from grapefruit, inhibits KRAS downstream pathway and sensitizes non-small-cell lung cancer A549 cells to adriamycin.
Hung LVM; Moon JY; Ryu JY; Cho SK
Phytomedicine; 2019 Oct; 63():153000. PubMed ID: 31280139
[TBL] [Abstract][Full Text] [Related]
6. C-Met inhibitor MK-8003 radiosensitizes c-Met-expressing non-small-cell lung cancer cells with radiation-induced c-Met-expression.
Bhardwaj V; Zhan Y; Cortez MA; Ang KK; Molkentine D; Munshi A; Raju U; Komaki R; Heymach JV; Welsh J
J Thorac Oncol; 2012 Aug; 7(8):1211-7. PubMed ID: 22617250
[TBL] [Abstract][Full Text] [Related]
7. Higher levels of c-Met expression and phosphorylation identify cell lines with increased sensitivity to AMG-458, a novel selective c-Met inhibitor with radiosensitizing effects.
Li B; Torossian A; Sun Y; Du R; Dicker AP; Lu B
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):e525-31. PubMed ID: 22836051
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
[TBL] [Abstract][Full Text] [Related]
9. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway.
Lin CC; Yeh HH; Huang WL; Yan JJ; Lai WW; Su WP; Chen HH; Su WC
Am J Respir Cell Mol Biol; 2013 Aug; 49(2):241-50. PubMed ID: 23526220
[TBL] [Abstract][Full Text] [Related]
10. USP14 Regulates DNA Damage Response and Is a Target for Radiosensitization in Non-Small Cell Lung Cancer.
Sharma A; Almasan A
Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32887472
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of AKT Enhances the Sensitivity of NSCLC Cells to Metformin.
Jang SK; Hong SE; Lee DH; Kim JY; Kim JY; Hong J; Park IC; Jin HO
Anticancer Res; 2021 Jul; 41(7):3481-3487. PubMed ID: 34230143
[TBL] [Abstract][Full Text] [Related]
12. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
Xia A; Li H; Li R; Lu L; Wu X
Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933
[TBL] [Abstract][Full Text] [Related]
13. High expression of Rad51c predicts poor prognostic outcome and induces cell resistance to cisplatin and radiation in non-small cell lung cancer.
Chen X; Qian D; Cheng J; Guan Y; Zhang B; Ding X; Zeng J; Chen X; Er P; Zhang F; Zhao N; Chen X; Zhao L; Yuan Z; Pang Q; Wang P
Tumour Biol; 2016 Oct; 37(10):13489-13498. PubMed ID: 27465554
[TBL] [Abstract][Full Text] [Related]
14. GSK-3β inhibits autophagy and enhances radiosensitivity in non-small cell lung cancer.
Ren J; Liu T; Han Y; Wang Q; Chen Y; Li G; Jiang L
Diagn Pathol; 2018 May; 13(1):33. PubMed ID: 29793508
[TBL] [Abstract][Full Text] [Related]
15. DNA damage response (DDR) pathway engagement in cisplatin radiosensitization of non-small cell lung cancer.
Sears CR; Cooney SA; Chin-Sinex H; Mendonca MS; Turchi JJ
DNA Repair (Amst); 2016 Apr; 40():35-46. PubMed ID: 26991853
[TBL] [Abstract][Full Text] [Related]
16. Metformin increases the radiosensitivity of non-small cell lung cancer cells by destabilizing NRF2.
Sun X; Dong M; Gao Y; Wang Y; Du L; Liu Y; Wang Q; Ji K; He N; Wang J; Zhang M; Gu Y; Song H; Zhai H; Feng L; Xu C; Liu Q
Biochem Pharmacol; 2022 May; 199():114981. PubMed ID: 35227644
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2/M cell cycle arrest.
Sarin N; Engel F; Kalayda GV; Mannewitz M; Cinatl J; Rothweiler F; Michaelis M; Saafan H; Ritter CA; Jaehde U; Frötschl R
PLoS One; 2017; 12(7):e0181081. PubMed ID: 28746345
[TBL] [Abstract][Full Text] [Related]
18. Radiosensitizing effects of ectopic miR-101 on non-small-cell lung cancer cells depend on the endogenous miR-101 level.
Chen S; Wang H; Ng WL; Curran WJ; Wang Y
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1524-9. PubMed ID: 22014955
[TBL] [Abstract][Full Text] [Related]
19. FOXC2 promotes epithelial-mesenchymal transition and cisplatin resistance of non-small cell lung cancer cells.
He Y; Xie H; Yu P; Jiang S; Wei L
Cancer Chemother Pharmacol; 2018 Dec; 82(6):1049-1059. PubMed ID: 30302523
[TBL] [Abstract][Full Text] [Related]
20. Attenuation of the DNA damage response by transforming growth factor-beta inhibitors enhances radiation sensitivity of non-small-cell lung cancer cells in vitro and in vivo.
Du S; Bouquet S; Lo CH; Pellicciotta I; Bolourchi S; Parry R; Barcellos-Hoff MH
Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):91-9. PubMed ID: 25835621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
